BIO’s Clinical Trial Disclosure Policy Allows Researchers Access To Data On Approved Medicines
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotechnology Industry Organization’s principles on clinical trial data sharing mirror those released by PhRMA last year; BIO suggests FDA conduct a pilot program on data sharing.
You may also be interested in...
J&J’s Clinical Data Disclosure Strategy Focuses On Collaboration With Yale University Group
In what appears to be the most expansive policy to date on release of clinical trial data, J&J will use an existing outside group and will share full clinical study reports and patient-level data regardless of when the studies were conducted.
Clinical Trials Transparency: EMA Delay Gives Industry Initiative More Time To Take Root
EMA’s plans for access to clinical trials data not set to be ready until well into 2014.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.